medacorp event updat immuno-oncolog washington dc
medic meet american colleg prosthodontist american pancreat associ
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
roundtabl highlight evolut market shift valu acceler
bottom line follow hcit distribut roundtabl recent host new york
continu believ hcit stock focus shift value-bas care remain
attract hcit coverag evol health op remain top pick hcit group
also believ op well posit monet live
healtheint platform hcit distribut roundtabl host two medacorp
panel first focus state electron medic record market come
away slightli cautiou allscript mp feedback mix
believ benefit standard amid hospit consolid
second panel focus shift value-bas care sound shift may gain
steam one kol predict amount revenu risk-bas arrang may grow
remain best posit capit secular shift
view remain one top pick hcit coverag
vendor standard main driver demand
epic lone beneficiari vendor standard
shift valu continu may acceler near futur well posit
athn mp offer excel physician product might need chang busi model shift
valu continu
revenu adjust non-gaap mm ep adjust street-compar basi ex
fa expens non-cash expens
revenu present mm non-gaap report exclud acquir amort stock comp
expens transact cost
ep exclud stock comp transact expens purchas account adjust
hix rate increas polici shift cnc/moh growth flattish
bottom line analysi hix price across industri specif
coverag op op op ci op select profit nfp
cross shield suggest subsid exchang stabil mm member flattish
margin deregul short-term individu polici drive growth much
overal rate increas meaning double-digit increas
amid chang polici competit landscap deregul short-term insur
individu market repeal individu mandat one-year insur provid fee
hipf moratorium mark regulatori competit hix landscap mm
member overal membership expand geograph footprint four new state
nc sc tn pa rate increas driven increas largest state fl tx
expect could grow exchang busi low doubl digit adequ
meet top-lin guidanc margin remain flattish hix also repres
total membership averag rate increas driven increas signific
enrol tx could also see low doubl digit growth flattish margin whose
membership exposur signific exit less like view meaning
impact exchang averag rate increas ga
substanti hix presenc mandat decreas ci hix exposur file modest
rate increas nfp blue show mix result rate hcsc report decreas
fl success hix player report increas smaller health plan
oscar bright new entrant competit increas state analysi keep us
cautious optimist exchang support busi segment growth margin
compani without domin fundament perform
open enrol underway ca begin state
hix price analysi suggest insur see averag rate increas meaning
saw double-digit increas
expect hix subsid marketplac see flattish growth stabil mm mm member
stronger growth short-term individu market member combin
uninsur mix shift unsubsid exchang market
trump administration/hh creat market outsid hix
mm member overal membership estim see overal rate increas
driven increas largest state fl tx expect could grow low doubl
digit adequ meet top-lin guidanc margin remain flat
hix also repres total membership averag rate increas driven
increas signific enrol tx could also see low doubl digit growth flattish
whose membership exposur signific exit less like view see
meaning impact exchang top-lin growth profit
ci maintain hix exposur membership view less like see
meaning impact exchang revenu growth profit
nfp show mix rate chang decreas hcsc plan five state
fl report increas
competit mco also increas state ad new insur see
incumb expand zero counti bare insur cover enrolle
price headwind biosimilar eros emerg despit aimovig pt
averag dcf price-to-earnings p/sale
bottom line yesterday report result beat consensu estim revenu
earn larg line above-consensu forecast despit
solid result see enough valuat upsid recommend stock given
signific headwind face portfolio aimovig great start repatha may yet becom
meaning contributor sale pipelin emerg product either small
distant move needl valuat
quarter total revenu consensu
estim
revenu million dilut non-gaap ep
commerci challeng challeng catalyst path keep us mp pt
 methodolog risk-adjust sum-of-part analysi discount rate
bottom line clovi report disappoint rubraca revenu miss consensu
estim guid minim growth expect pressur share
continu concern market dynam parp inhibitor class ovarian cancer persist
term market uptak well competit dynam base challeng
lower rubraca sale estim believ investor may find valuat compel
level remain sidelin given persist parp inhibitor commerci challeng
lack near-term transform catalyst diminish prospect strateg option lower
pt remain mp
rubraca sale miss growth ovarian cancer remain elus
clovi fight share detail differenti data commerci execut concern remain
potenti first mover advantag prostat could key
lower rubraca sale estim pt
despit pt current level remain market perform
tsro may pressur investor fear similar headwind
earn solid quarter bar easiest y/i comp
ev/sal multipl sale
bottom line market close report sale -- slightli ahead
us consensu -- reiter sale guidanc
repres growth midpoint compar us consensu
strongest sale growth quarter sinc -- get credit -- note
sale growth came compani easiest y/i compar sale essenti
flat y/i comp get increasingli tougher move year sens
investor hope take pressur rest-of-year ramp
share could under-perform tomorrow believ driver
place acceler growth comp-adjust basi move year notabl clinic
specialist continu ramp product note increas new user exist account
-- encourag data point view sustain core busi growth eclips
coronari trial continu enrol drive increas awar around coronari atherectomi
orbusneich product launch repres low watermark year
driver make reiter guidanc achiev admittedli somewhat reliant
ex-cor busi growth long-term continu believ repres sustain double-
digit growth stori next year compani core busi maintain signific
competit advantag calcifi below-the-kne lesion within peripher drive
above-market growth well grow market-lead posit highli under-penetr
sign end tunnel sell-off overblown
pro-forma ebitda leverag
bottom line encourag print anoth data point attest
turnaround reiter pt view sell-off overblown ebitda
beat driven solid price improv volum margin expans support underli
opex trend ebitda cffo guidanc reiter despit increas interest expens
encourag manag commentari call convers cfo tom
guid mid-teen ebitda margin next month combin
top-lin growth improv volum trend ration portfolio superior market
cost effici see sell-off relat cash flow crunch delay last round
divestitur toward paydown senior debt stub matur juli overblown
also comfort better portfolio market network contract larg off-set one-tim
price tailwind price lack hurrican view volum improv
margin turnaround key strengthen balanc sheet cash flow posit compani
maintain ebitda estim mm mm look forward
color outlook earn potenti margin expans
posit surpris ebitda price growth improv volum trend opex-driven
ebitda cffo guidanc reiter reassur
see sell-off cash flow concern delay divestitur temporari setback sell-
overblown yesterday
margin expans mid-teen key success turnaround improv balanc sheet cash
price outlook look better expect improv portfolio offset challeng comp
valuat attract view post sell-off continu fundament improv cash
posit unlock valu
revenu million bad debt expens ep present ex one-tim item
strong quarter bring growth back track ahead co-
combin sale dcf analysi wacc lt growth
bottom line remain outperform given view cologuard highli under-
penetr strong popul believ could deliv
penetr revenu long-term penetr today deliv solid
quarter test ahead us street rais full year guid
believ stock trade higher see realiz dramat revenu ramp
rep start co-promot cologuard believ estim full year guid
cologuard deliv ahead major co-promot ramp
focu remain co-promot commerci team sens urgenc make
invest growth capac expans indic expans electron order broader pipelin
remain agenda
revenu non-gaap ep exclud charg
small china studi safeti signal probabl storm teacup
bottom line fibrogen stock under-perform biotech group market
last day base concern outlook hif-ph inhibitor roxadustat
emerg extens phase trial program note recent research link
import result product futur stock valu integr mace analysi
combin phase trial encompass patient analysi expect complet
announc around end determin whether roxadustat particular
minor major blockbust drug class critic question whether roxadustat non-inferior
inferior superior epoetin alfa term major advers cardiac event mace risk secondarili
roxadustat compar placebo endpoint maintain pt
late last week number poster present american societi nephrolog
roxadustat phase studi china japan rais concern drug might actual
associ increas risk event believ concern behind
rel unconcern result sinc studi small event number
low result contribut us/eu combin mace analysi appear
error report laboratori possibl observ certain studi site china
among three chief concern aros poster cardiovascular cv event hyperkalemia
discontinu two quit ration explain hyperkalemia discontinu third cv
event base small number
 methodolog ev/ebitda ebitda
bottom line rais estim pt beat solid initi
ebitda growth guidanc rang addit upsid deal includ mission
solid beat across board volum price growth ebitda
margin expans initi growth guidanc ex deal valid strong convict
best breed name pois acceler growth normal guidanc
outsiz share gain tax reform optim capital-expenditure across servic line improv ambulatori
asset level play field profit peer price growth driven improv payor mix
lead market share posit attract msa capit deploy offer inorgan growth
exist new market bs solid debt ebitda greater cap ex
plan annual dividend yield revenu ebitda go
mm respect revenu ebitda acceler mm
addit upsid mission pt move contempl ev ebitda
estim look forward tenur new ceo hazen outgo
ceo milton johnson close success run quarter
solid revenu ebitda beat strong volum price growth suppli effici
ss adj admiss growth solid outpac peer see improv demand market
well market share gain expect continu drive volum
price solid driven improv acuiti servic line growth potenti remain
rais revenu ebitda back solid
patient staff safe evacu hurrican michael florenc impact hca panama
citi south carolina facil estim mm
rais estim initi ebitda growth target addit upsid pend
balanc capit deploy opportun aid tax reform across organ capital-expenditure
reiter op increas pt
revenu million bad debt ep present ex one-tim item
 methodolog ev/sal multipl appli sale
bottom line mix similar -ve area play last
qtr howev unlik last qtr sure us growth acceleration/org revenue out-performance
entir outweigh qtr sizeabl vs margin/ep miss revenue under-perform
investor mind -- -accompani big margin/ep guidanc cut -- especi amid ceo
transit head sale departur announc unexpectedli last week
regard latter wrote previous link think leadership chg bode well improv
futur execution/mgmt account neg near-term takeout prospect stay mp
still like greater convict pathway sustain hsd top-lin growth
time drive margin expans -- -where execut continu challeng downward
estim revis continu pt reduc vs slightli lower sales/ebitda
multipl grp multipl contract appli higher revenue also lower ebitda/ep estim
revenue outlook increas margin ep guidanc lower
regard puls surgic intellig platform -- -mgmt answer navigation/robot -- -not much info
provid beyond co disclos nass
pt decreas vs lower estim still believ share valuat
support justifi catch-up multipl expans vs group shr trade wide
discount view
non-gaap ep exclud item amort expens revenu mm
behind expect turnaround slow reduc pt
 methodolog adjust ep
growth miss top line adjust legal benefit
lower tax rate also miss leerink consensu ep book increas
impress y/i manag attribut light revenu larger complex deal
take longer implement disclos sign anoth seven-figur
deal quarter six deal worth encourag third
consecut quarter book growth attrit increas ttm basi
quarter driven health system affili custom may long-term issu view
guidanc reduc due increas attrit unexpect mix shift deal
revis guid disappoint rel prior estim manag continu guid
high-single-digit revenu growth oper margin continu
book growth think unlik deliv high-single-digit revenu
growth maintain mp pt declin
mix result third consecut quarter book growth
continu win larg deal
guidanc reduc revenu attrit disappoint
continu book growth robust pipelin amid continu uptick attrit
measur implement timelin month
custom upgrad weigh way forc client updat
updat model quarter maintain market perform
non-gaap ep exclud acquir amort acquisit cost stock comp litig cost
recap consum continu drive growth question remain
dx
bottom line view high growth research tool consum engin high
margin busi profil consist consum instrument
recent acquisit exosom diagnost outlook also lever diagnost deliv
solid quarter yesterday view stock trade time reimburs
exosom epi test remain uncertain could push make challeng hit
estim laid earlier growth also lumpi diagnost genom segment
make challeng pars growth acd high growth rna-ish platform protein
scienc largest segment deliv solidli drove quarter
protein scienc deliv solidli quarter
time reimburs exosom dx epi remain unclear
remain confid epi medicar coverag lower estim given near-term reimburs
revenu ep exclud charg amort intang
wait full phase result reiter outperform pt
analysi discount rate termin growth rate
bottom line yesterday market close acceleron report financi result confirm
main clinic trial timelin data present manag confirm obviou
show full result joint medalist believ pivot trial
decemb ad detail design enrol addit command
trial earlier line myelodysplast syndrom md manag team seem still
luspatercept expect reveal addit indic trial drug
come month acceleron believ base five current indic develop
could reach patient us eu lack treatment option
compani re-affirmed timelin neuromuscular program on-going phase studi
facioscapulohumer muscular dystrophi fshd cmt charcot-marie-tooth
diseas anoth neuromuscular drug phase second half
see signific de-risk proof concept mileston program even two
partner prepar launch luspatercept earli reiter rate outperform
maintain price target
revenu mm ep present
posit gist updat pathway defin btd
bottom line blueprint highlight recent pipelin progress earn investor
focus updat avapritinib data gastrointestin stromal tumor gist present
novemb meet rome updat key near-term catalyst featur
first look patient expect outlin registr strategi
set base fda feedback blueprint plan submit nda base
phase arrow trial r/r ret fusion lung/thyroid patient r/r ret mutant mtc
patient avapritinib receiv breakthrough therapi design btd advanc system
mastocytosi sm patient enrol pivot pathfind trial set
total blueprint expect six pivot trial underway sever pursu
ep modestli consensu revenu
bottom line aet report ep beat driven revenu sg off-set tax rate
miss consolid miss bp notabl commerci deterior yoy given
lower favor prior period develop relat provid arbitr rule relat
date servic commerci headwind off-set improv govern though
prior period favor develop weaker govern busi day claim payabl
deterior day yoy improv sequenti day said busi mix chang
manag host confer call light pend op deal exhibit
updat jakafi miss inventori drawdown pipelin remain track
bottom line report jakafi revenu consensu sale
impact inventori headwind quarter pipelin remain track
snda ruxolitinib gvhd graft vs host diseas accept prioriti review pdufa
date set feb expect share weaker follow below-consensu jakafi
sale absenc pipelin updat materi chang invest thesi
fundament continu see jakafi franchis worth per share suggest minim
valu attribut pipelin note investor longer term time horizon may
becom construct share level remain mp pt
revenu mm ep
discount rate termin growth rate
bottom line approv arikayc end launch approv drug
nontubercul mycobacteri ntm lung diseas caus myobacterium avium complex
link provid limit visibl launch sinc still earli stage look forward
earn compani report sale first time gaug launch post-approv
confirmatori studi updat front-lin set potenti significantli expand
market opportun beyond current label refractori patient reiter op pt
revenu
bottom line report strong quarter deliv revenu ahead us
street pharma servic clinic genet test deliv
slightli higher contribut pharma servic also rais revenu guid higher
end previous guid rang ep guid
vs believ stock react posit given solid
perform quarter rais guid recent announc acquisit
genoptix make lead one stop-shop oncolog test provid
best-in-class liquid biopsi opportun massiv high growth market
return biotech share buyback
insight trump part price propos
program difficult implement think could increas list
growth back new mkt come focu
 methodolog dcf translat ev/sal
afirma deliv impress quarter guid rais outlook
outperform market cap price price target methodolog averag
dcf sale
 rais solid sg off-set tax rate miss
 methodolog cash ep
sleep rest assur inspir therapi initi op pt
discuss around approv prospect gener advair posit earn
manag indic complet respons letter june includ minor
label chemistri manufactur control relat question
submit respons mid-juli standard three month goal date
although hope sinc product prioriti design approv could come
manag emphas addit data requir part respons
remain readi launch upon approv
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
compani develop varlitinib indic high preval asia includ
biliari tract cancer gastric cancer
asln expect multipl data readout includ
interim readout phase i/ii studi varlitinib gemcitabin cisplatin line
top-lin data global phase ii/iii studi varlitinib folfox co-
interim data ph ii studi dhodh inhibitor acut myeloid leukemia
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi link
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
given superl clinic data present date expect fda approv
nov link note
larotrectinib loxo lead agent potent specif pan-trk tropomyosin receptor
kinas inhibitor combat basket tumor includ lung breast colon
trk biomark individu estim us
larotrectinib next-gen trk inhibitor partner bayer hold
ex-u commerci right pay loxo tier double-digit royalti ex-u sale
loxo bayer co-develop us cost profit split loxo
receiv up-front payment potenti receiv mileston payment
us ou larotrectinib
project combin larotrectinib peak probability-of-success
adjust sale us europ larotrectinib eu
submit august
dec epo patent challeng relat rubraca ovarian prostat
dec european patent offic epo hear oral argument render
opinion patent challeng camsyl salt patent provid ip protect
eu drug rubraca
challeng file divis sandoz anonym parti contend
epo patent recent grant clovi novel -- argument preliminari
opinion agre cite prior art exist applic file
medacorp specialist review preliminari opinion render april felt
opposit strong argument could result narrow patent claim
claim narrow eu could make invent step difficult
uphold unexpect product attribut may compar broadli potenti
open door prior art consid
view eu patent challeng relev impact potenti
takeout option potenti read-through us exclus
composit matter patent expir without addit patent support drug
intellectu properti ip runway relev us patent howev like
hotli debat even dec goe poorli
sourc leerink research compani inform factset price prior day
fda adcom joint psychopharmacolog drug drug safeti risk
fda adcom vaccin relat biolog product
pdufa revefenacin lama copd
fda adcom joint anesthet analges drug product drug safeti
pdufa roxicodon abuse-deterr formul immediate-releas single-
north carolina dhh award rfp transit medicaid program manag
may texa hhsc award rfp star plu medicaid manag care program
american colleg prosthodontist
american societi hematoloy abstract releas et
associ molecular patholog
american associ scientist
societi immunotherapi cancer adap imdz iph tril
intern confer societi medic innov technolog
intern societi traumat stress studi
american associ studi liver diseas
american societi cytopatholog
societi neuro-oncolog
american colleg allergi asthma immunolog
intern societi pediatr oncolog
radiolog societi north america
life scienc biolog engin confer
societi urolog oncolog
intern feder adipos therapeut scienc
asian pacif societi respirolog
american societi hematolog
manag end sell season
univers coverag
calendar event
model model recent
updat pleas contact leerink repres wish review
biopharma preview gener pain women health anti-infect
 biotech earn unlik offer much excit best
hcit distribut preview price pressur continu gener
medic suppli devic individu co preview cardio large-cap diversifi
medic suppli devic individu co preview ortho supplies/cap equipment/
payor servic posit catalyst
 west coast alzheim kol provid discourag view amyloid aaic
 half full half empti alzheim diseas puls call takeaway market perform
 biopharma ipo part capit inflow predict revers
biopharma price pledg made biopharma what happen
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
biopharma novel pain treatment class bar far limit potenti
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 glucagon rescu progress schedul outperform
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
medic suppli devic la med-tech day deep dive physician view
medic devices-cardiolog hr takeaway cabana unlik chang af practic
medic devic survey support market share re-gain assumpt
medic suppli devic initi takeaway sage robot continu gain
medic devic leerink healthcar confer panel devic penetr set
biopharma product price contribut growth grow
biopharma price pledg made biopharma what happen
biopharma minim impact script npf chang could other follow
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
hcit distribut state auditor report seem show competit price
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
-- flash eu patent liabil suggest valu downsid outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
 foundat franchis preview forward-i data outperform
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
iph fp azn partnership highlight strateg shift first commerci foray pt
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
outperform
outperform
perform
outperform
initi coverag target oncolog
initi fine-tun btk autoimmun
perform
outperform
 research micro-dystrophin
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
 cll survey suggest signific opp next-gen btk improv
 medacorp payor survey highlight favor statu quo intact orphan
 parp survey highlight enthusiasm maint re-tx suggest
 survey yoy util slow shift op posit mco
op/asc link link link
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 medacorp survey highlight driver headwind ali pt outperform
 awak w/ solriamfetol rais est follow medacorp survey pt
major medacorp survey lung cancer posit azn
medic suppli devic survey healthi util trend still risk-
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
 survey confirm bullish view adcetri frontlin hl reiter op pt
teva rais austedo sale analysi posit medacorp physician survey
 leadership seri growth momentum sustain stemi data catalyst
 open ablat atriclip drive near term growth mi longer term
 leadership seri call highlight upsid potenti neuromodul outperform
 leadership seri busi sourc lt upsid outperform
 differenti poc signific runway impli upsid pt
 leadership seri growth acceler strong gener outperform
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
